Note: Ingredients listed on restricted chemical lists
EC/CAS
14807-96-6
Name of the chemical
Talc
Concentration
N/A
EC/CAS
1317-70-0
Name of the chemical
Titanium dioxide in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm
Concentration
N/A
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
EC/CAS
9005-25-8
Name of the chemical
Starch
Concentration
N/A
EC/CAS
238-877-9
Name of the chemical
Talc: Hydrated magnesium silicate
Concentration
N/A
EC/CAS
215-280-1
Name of the chemical
Titanium dioxide in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm
Concentration
N/A
EC/CAS
209-150-3
Name of the chemical
Aluminium, zinc, magnesium and calcium stearates
Concentration
N/A
EC/CAS
215-168-2
Name of the chemical
Iron Oxide Red
Concentration
N/A
EC/CAS
232-679-6
Name of the chemical
Starch
Concentration
N/A
General Information
Revision date
2018-09-29
Product name
Vraylar
Product Synonyms
Cariprazine
Manufacturer Name
Allergan plc
Emergency telephone
Call CHEMTREC Day or Night
Icons in SDS
Company Information
company name
Allergan plc
e-mail address of the competent person responsible for the Safety Data Sheet
SDS@Allergan.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H361
Hazard statements
Code
Statements
H361
Suspected of damaging fertility or the unborn child
Section 2
2.1 Classification of the substance or mixture
OSHA Regulatory Status This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Reproductive toxicity Category 2
2.2 Label elements
Emergency Overview Warning
Hazard statements
H361 - Suspected of damaging fertility or the unborn child Appearance Capsule Physical state Solid Odor No information available Chemical Name Symptoms Cariprazine Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. This medication is not approved for the treatment of patients with dementia-related psychosis Most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo) were (6.1) Schizophrenia extrapyramidal symptoms and akathisia; Bipolar mania: extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness Chemical Name
Medical Conditions Generally Aggravated by Exposure
Cariprazine This medication is contraindicated in patients with history of a hypersensitivity reaction tocariprazine. Reactions have ranged from rash, pruritus, urticaria, and events suggestiveof angioedema (e.g., swollen tongue, lip swelling, face edema, pharyngeal edema, andswelling face).
Precautionary statements
P201 - Obtain special instructions before use P202 - Do not handle until all safety precautions have been read and understood P281 - Use personal protective equipment as required P308 + P313 - IF exposed or concerned: Get medical advice/attention P405 - Store locked up P501 - Dispose of contents/ container to an approved waste disposal plant P280 - Wear protective gloves/protective clothing/eye protection/face protection
Further information
Unknown Acute Toxicity 100% of the mixture consists of ingredient(s) of unknown toxicity Over the counter drugs in their solid form are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 20 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limit may be surpassed, than can be considered hazardous